Jennison Associates LLC Purchases New Shares in Upstream Bio, Inc. $UPB

Jennison Associates LLC purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, Holdings Channel.com reports. The fund purchased 288,847 shares of the company’s stock, valued at approximately $7,842,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of UPB. GF Fund Management CO. LTD. acquired a new stake in Upstream Bio during the 4th quarter valued at $29,000. Torren Management LLC acquired a new stake in Upstream Bio during the 4th quarter valued at $30,000. BNP Paribas Financial Markets increased its holdings in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares in the last quarter. Legal & General Group Plc increased its holdings in Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after purchasing an additional 2,887 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on UPB shares. Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target for the company. in a report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Upstream Bio Stock Performance

NASDAQ UPB opened at $9.40 on Friday. The stock has a fifty day moving average of $9.03 and a 200-day moving average of $20.00. The stock has a market capitalization of $511.55 million, a P/E ratio of -3.52 and a beta of 1.29. Upstream Bio, Inc. has a 52 week low of $7.25 and a 52 week high of $33.68.

Upstream Bio (NASDAQ:UPB) last released its earnings results on Thursday, March 26th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.52 million. Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. Equities research analysts forecast that Upstream Bio, Inc. will post -3.02 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.